CALT News and Press, Calliditas Therapeutics AB From 01/12/23

Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...

Summary 2023 should be a year of progress on kidney disease, with multiple catalysts lined up from multiple companies. Chinook Therapeutics, Inc. has the best risk-reward based on: i) valuation; ii) diversity of pipeline (ERA and anti-APRIL); and iii) clear catalyst in Q3 2023 (phase 3 ...

Swedish biopharma Calliditas Therapeutics ( NASDAQ: CALT ) announced Friday that regulators in China recommended the priority review for its marketing application seeking approval of kidney disorder therapy Nefecon. In November, Calliditas ( CALT ) announced that China's National ...

China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy PR Newswire STOCKHOLM , Dec. 30, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced th...

Calliditas Therapeutics' ( NASDAQ: CALT ) CEO Renée Aguiar-Lucander has acquired 50,000 shares through its warrant program 2019/2022. Following the new subscription, Aguiar-Lucander holds 643,000 common shares in the company. The majority of the members of management who ...

Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022 PR Newswire STOCKHOLM , Dec. 21, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO ...

Calliditas ( NASDAQ: CALT ) signed a licensing agreement with Viatris ( NASDAQ: VTRS ) to register and commercialize Nefecon in Japan for treating chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN). Under the agreement, Sweden-based Calliditas is en...

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan PR Newswire Calliditas announces that it has entered into an agreement with Viatris to bring Nefecon®, a specialty therapy focused...

Calliditas to host fireside chat with its China commercial partner, Everest Medicines PR Newswire STOCKHOLM , Dec. 9, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial par...

Calliditas Therapeutics ( OTCPK:CLTEF ) ( NASDAQ: CALT ) said China's National Medical Products Administration (NMPA) accepted to review Everest Medicines' new drug application (NDA) for kidney disease drug Nefecon. Calliditas said that Nefecon, if approved, w...